Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant Melanoma
Go back to Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant MelanomaArray Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 15.10 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $15.10 | 52 Week High | $7.27 | |||
Open | $15.10 | 52 Week Low | $2.39 | |||
Day High | $15.10 | P/E | N/A | |||
Day Low | $15.10 | EPS | $-0.61 | |||
Volume | 1,374 |